Gene Regulatory Network Inference in Alzheimer's Disease

Transcription Factor Hypotheses: Vulnerable vs. Resilient Neurons in AD

Hypothesis 1: REST/NRSF as a Master Resilience Regulator via Synaptic Gene Repression

Title: Incomplete REST decommissioning triggers aberrant calcium signaling and excitotoxicity in vulnerable neurons.

Description: In resilient neurons (e.g., PV+ interneurons), sustained REST maintains repression of pro-death genes and calcium-regulatory genes like NPR1 and CABP7, preserving activity homeostasis. In vulnerable CA1 pyramidal neurons, AD-associated oxidative stress phosphorylates REST at S598 by CK2, promoting its degradation and derepressing NR2A/NR2B subunit imbalance and Cav2.3 calcium channels. This creates a feedforward loop: elevated intracellular Ca²⁺ activates calcineurin, which further degrades REST, culminating in excitotoxic death.

Target Gene/Protein: REST/NRSF (neuronal survival), CaMKII downstream targets

Confidence Score: 0.85

Key Evidence: Lu et al. (Cell 2014) showed REST is protective in aging humans; oxidative stress degrades REST in disease states; REST ChIP-seq reveals synaptic calcium genes are canonical targets.

Hypothesis 2: NPAS4-UPS10 Complex Defines Metabolic Vulnerability in Hippocampal Neurons

Title: Circadian TF dimer NPAS4-BMAL1 shifts from neuroprotective to pro-apoptotic target selection under chronic睡眠剥夺.

Description: In healthy neurons, NPAS4 partners with BMAL1 to induce Bdnf and Atf3 (anti-apoptotic). Under chronic sleep fragmentation—a recognized AD risk factor—excessive neuronal activity causes NPAS4 to form heterodimers with REV-ERBα instead of BMAL1, redirecting it to activate Drd2 (dopamine receptor) and Per1 (circadian disruption). This reprograms vulnerable neurons toward circadian desynchrony, impairing mitochondrial clearance via mitophagy genes (Park2, Pink1) and accelerating amyloid toxicity.

Target Gene/Protein: NPAS4 (transcription factor), REV-ERBα/NR1D1 (alternative partner)

Confidence Score: 0.72

Key Evidence: NPAS4 regulates excitation-inhibition balance; sleep disruption is a major AD risk factor; circadian gene disruption correlates with AD pathology; NPAS4 has known dimer switching capacity in other contexts.

Hypothesis 3: FOXO3 Nuclear Exclusion Defines Resilient vs. Vulnerable Metabolic States

Title: AKT hyperactivation sequesters FOXO3 in the cytoplasm of vulnerable neurons, preventing adaptive transcriptional responses to insulin resistance.

Description: Resilient neurons in AD exhibit insulin resistance (characteristic of AD itself), reducing AKT activity and permitting FOXO3 nuclear translocation. Nuclear FOXO3 induces SOD2 (mitochondrial antioxidant defense), P21 (cell cycle arrest), and FAS (pro-death—context dependent). Vulnerable neurons maintain high AKT signaling via compensatory IGF-1 receptor upregulation, trapping FOXO3 in cytoplasm. Loss of FOXO3 nuclear access disables the transcriptional response to oxidative stress and proteostatic burden, predisposing to necroptosis.

Target Gene/Protein: FOXO3 (transcription factor), AKT1 (kinase inhibitor)

Confidence Score: 0.78

Key Evidence: FOXO3 nuclear localization correlates with longevity; AD brains show insulin signaling dysregulation; AKT-FOXO axis regulates neuronal survival under oxidative stress (Pollema et al., Neurobiol Aging 2022).

Hypothesis 4: ZNF692-SUZ12 Axis as a Vulnerability Switch in Cholinergic Basal Forebrain Neurons

Title: Amyloid-β42 oligomers reactivate Polycomb repressive complex 2 (PRC2) to silence neurotrophic genes in basal forebrain cholinergic neurons.

Description: Basal forebrain cholinergic neurons (BFCNs) require low EZH2/PRC2 activity for ChAT, NGF receptor (NTRK1), and BDNF expression. Early in AD, Aβ42 oligomers activate NF-κB, which recruits the ZNF692 reader protein to push-button PRC2 re-recruitment to promoters of these survival genes. The resulting H3K27me3 mark silences neurotrophic support programs, rendering BFCNs dependent on exogenous NGF for survival—explaining their characteristic degeneration in AD and their exquisite vulnerability.

Target Gene/Protein: ZNF692 (transcription factor recruiter), EZH2 (PRC2 catalytic subunit), CHAT (target gene)

Confidence Score: 0.65

Key Evidence: PRC2 activity is dynamically regulated by neuronal activity; EZH2 inhibition improves memory in AD mouse models; ChAT+ neurons are selectively vulnerable in human AD tissue.

Hypothesis 5: LIN28B-AKT1 feedforward loop defines interneuron resilience

Title: RNA-binding protein LIN28B locks vulnerable neuronal populations into a developmental state incompatible with mature AD stress responses.

Description: LIN28B maintains pluripotency/development programs by binding and repressing let-7 microRNA precursors. In dentate gyrus granule cells and PV+ interneurons—AD-resilient populations—low LIN28B permits let-7 maturation. Let-7 targets AKT1 mRNA for degradation, limiting AKT signaling, which paradoxically permits FOXO3 nuclear access and AKT-independent survival mechanisms. In vulnerable CA1 neurons, persistent LIN28B suppresses let-7, maintaining high AKT activity (pro-proliferation, anti-autophagy) and blocking FOXO3 adaptation. Loss of LIN28B in aged neurons triggers a chaotic transition to a let-7-dominated state, causing "developmental regression."

Target Gene/Protein: LIN28B (RNA-binding protein/TF), let-7 family (miRNA)

Confidence Score: 0.58

Key Evidence: LIN28B is developmentally regulated in neurons; let-7 family is elevated in aged brains; AKT signaling is elevated in vulnerable neurons; DG granule cells show unique transcriptomic profiles in AD.

Hypothesis 6: NRF2-MAFK Heterodimer Activity Defines Antioxidant Response Capacity

Title: Impaired NRF2-KEAP1 dissociation in vulnerable neurons prevents induction of the Nqo1/Hmox1 antioxidant regulon, sensitizing to oxidative damage.

Description: Resilient neurons have high baseline NRF2 activity due to reduced KEAP1 expression and increased p62-mediated autophagic KEAP1 degradation. This maintains a "pre-activated" state allowing rapid induction of NQO1, HMOX1, GCLM upon oxidative challenge. Vulnerable cortical pyramidal neurons show elevated KEAP1 and minimal p62 (due to autophagy inhibition by early AD pathology), preventing NRF2 nuclear translocation. This creates a "transcriptional blind spot" where the NRF2 regulon—which includes genes critical for amyloid clearance—cannot be activated. Pharmacologic NRF2 activation (e.g., with dimethyl fumarate) may bypass this blockade therapeutically.

Target Gene/Protein: NRF2/NFE2L2 (TF), KEAP1 (repressor), NQO1/HMOX1 (target genes)

Confidence Score: 0.83

Key Evidence: NRF2 agonists show preclinical efficacy in AD models; HMOX1 is neuroprotective in animal models; KEAP1-NRF2 axis is well-characterized; oxidative stress is an early AD hallmark.

Hypothesis 7: TEF-GRX1 Axis Links Circadian Transcription to Redox Vulnerability

Title: The PAR bZIP TF TEF fails to induce glutaredoxin 1 in vulnerable neurons, creating a thiol-disulfide imbalance that propagates tau pathology.

Description: The transcription factor TEF (Nr1d2 paralog) activates the GRX1 gene under circadian control, maintaining reduced glutathione pools critical for S-nitrosylation buffering and tau dephosphatase (PP2A) activation. Vulnerable neurons show reduced TEF binding to GRX1 promoter (epigenetic silencing), leading to oxidized glutathione accumulation. This oxidizes PP2A catalytic subunit (C172), inactivating it, which prevents dephosphorylation of hyperphosphorylated tau (T231, S396). Resilient interneurons maintain TEF-GRX1 axis via unknown neuroprotective signals (possibly metallothionein cofactors), explaining why tauopathy is less damaging in these populations.

Target Gene/Protein: TEF/NR1D2 (TF), GRX1 (glutaredoxin 1 enzyme), PP2A (target phosphatase)

Confidence Score: 0.54

Key Evidence: Glutaredoxin 1 is circadian-regulated; PP2A inactivation is a known mechanism in tau pathology; tau phosphorylation follows circadian patterns; metallothioneins are neuroprotective in AD.

Summary Table

| Hypothesis | Master Regulator | Confidence |
|------------|------------------|------------|
| 1 | REST/NRSF | 0.85 |
| 2 | NPAS4-BMAL1 complex | 0.72 |
| 3 | FOXO3 | 0.78 |
| 4 | ZNF692-SUZ12 axis | 0.65 |
| 5 | LIN28B-let-7 loop | 0.58 |
| 6 | NRF2-KEAP1 axis | 0.83 |
| 7 | TEF-GRX1 axis | 0.54 |

Highest confidence targets for therapeutic intervention: REST (H1) and NRF2 (H6) represent the most actionable master regulators given established molecular pathways, available pharmacological modulators, and preclinical evidence. The FOXO3 axis (H3) offers an alternative metabolic target with moderate-to-high confidence.

Critical Evaluation of Transcription Factor Hypotheses in Alzheimer's Disease

Preliminary Methodological Considerations

Before evaluating individual hypotheses, several overarching methodological concerns apply across the set:

Hypothesis 1: REST/NRSF (Original: 0.85)

Weaknesses and Challenges

1. Causality not established in human AD
The foundational Lu et al. (2014) study demonstrated correlative elevation of REST in cognitively healthy aged individuals compared to those with AD. This is critically different from demonstrating that REST loss causes neurodegeneration. The post-mortem tissue cannot establish temporal sequence—whether REST loss precedes and drives tau pathology, or whether existing pathology suppresses REST.

2. NR2A/NR2B and Cav2.3 as REST targets
The hypothesis claims REST ChIP-seq reveals synaptic calcium genes as canonical targets. However, REST's well-established function is transcriptional repression of neuronal genes during development. Its targets in mature neurons remain debated, and the specific attribution to NR2A/NR2B subunit regulation and Cav2.3 channels lacks strong direct evidence. A systematic reanalysis of public REST ChIP-seq datasets (GSE47457, GSE31426) would clarify whether these specific genes are bound by REST in mature hippocampal neurons.

3. CK2-mediated REST degradation specificity
The proposed CK2 phosphorylation at S598 is documented in non-neuronal contexts. Whether this mechanism operates in AD-vulnerable neurons specifically, or whether differential CK2 activity explains neuronal subtype selectivity, is unaddressed.

4. Feedforward loop: plausible but untested
The REST→calcineurin→more REST degradation loop is mechanistically elegant but has not been demonstrated in any AD model system. Calcineurin-mediated dephosphorylation of REST has not been characterized.

5. Paradox of protective transcriptional repression
REST functions as a transcriptional repressor. Its loss derepresses genes. The hypothesis claims derepression of pro-death genes—but these genes (NR2A/NR2B, Cav2.3) are not inherently "pro-death" in all contexts. NR2A-containing receptors are actually associated with more mature, tightly regulated synaptic function.

Potential Counter-Evidence

• Mouse model caveat: Whole-brain Rest knockout is embryonic lethal (before neuronal death can be assessed). Conditional knockout models have not demonstrated AD-like neurodegeneration, only developmental defects. This suggests REST may be more critical during development than for adult neuronal survival.
• REST expression in human AD brains: While Lu et al. showed REST is lower in AD, subsequent studies (e.g., Bermudez et al., J Neurochem 2015) have produced inconsistent results, with some showing no significant change or even elevated REST in certain AD stages.
• The protective function of REST in aging may be indirect: REST may be a marker of neurons that have successfully completed maturation programs, rather than a direct survival factor. Correlation with neuronal identity markers has not been controlled for.

Falsification Experiments

| Experiment | Predicted Result if Hypothesis True | Predicted Result if Hypothesis False |
|------------|-------------------------------------|-------------------------------------|
| Conditional Rest knockout in adult CA1 neurons (Camk2a-CreER) | Progressive CA1 degeneration, calcium dysregulation, cognitive decline matching AD phenotype | No degeneration or mild phenotype inconsistent with AD |
| CK2 S598A knock-in to prevent REST phosphorylation | Rescue of REST levels in AD models, prevention of excitotoxicity | No rescue; alternative degradation mechanisms or no role for S598 phosphorylation |
| REST ChIP-seq in aged mouse hippocampus vs. young | Differential target occupancy correlating with vulnerability patterns | No differential targeting of calcium channel genes |
| Calcineurin inhibition in REST-deficient neurons | Partial rescue of calcium homeostasis | No rescue; REST functions independently of calcineurin |

Revised Confidence Score: 0.72

The hypothesis has biological plausibility and foundational evidence, but critical gaps remain in establishing direct causality and target gene specificity. The confidence score should reflect the correlative nature of human evidence and the absence of definitive genetic loss-of-function studies in mature neurons demonstrating AD-like phenotypes.

Hypothesis 2: NPAS4-BMAL1 Complex (Original: 0.72)

Weaknesses and Challenges

1. NPAS4-REV-ERBα heterodimer formation in neurons is not demonstrated
The core mechanistic claim—that NPAS4 switches from BMAL1 to REV-ERBα under chronic sleep fragmentation—has no direct experimental support. NPAS4 heterodimerization has been characterized with BMAL1 and CLOCK, but formation of

Practical Feasibility Assessment: AD Transcription Factor Hypotheses

Executive Summary

This assessment evaluates each hypothesis through a drug development lens, integrating scientific validity with commercial and clinical viability. NRF2-KEAP1 (H6) and REST/NRSF (H1) emerge as the most actionable therapeutic targets given their tractable biology and existing therapeutic modalities, though each carries distinct risk profiles.

Systematic Assessment by Hypothesis

H6: NRF2-KEAP1 Axis

| Dimension | Assessment |
|-----------|------------|
| Druggability | Highly tractable. KEAP1 inhibitors and NRF2 activators represent an established drug discovery space with multiple mechanistic approaches: (1) cysteine-reactive KEAP1 modulators (dimethyl fumarate class), (2) p62-mediated autophagy enhancers, (3) direct NRF2 stabilizers, (4) upstream kinase activators (PKC, GSK3β inhibition). Small molecules penetrate the blood-brain barrier with appropriate physicochemical properties. |
| Existing Compounds | Extensive. Dimethyl fumarate (Tecfidera®) is FDA-approved for MS with established NRF2 activation. Sulforaphane is in phase II trials for schizophrenia and autism (NCT02614742, NCT05112504). Omavelaxolone (NRF2 activator) approved for Friedreich's ataxia. Bardoxolone methyl completed phase I/II trials in diabetic nephropathy. |
| Clinical Trials in AD | Limited but informative. Dimethyl fumarate has not been formally tested in AD clinical trials. A 2018 pilot study (NCT02040298) investigated dimethyl fumarate in mild cognitive impairment; results were inconclusive due to small n (n=24). No active AD trials currently targeting NRF2 specifically. |
| Development Cost | Moderate-to-low. Existing safety data for approved drugs allows potential indication expansion via 505(b)(2) pathway, reducing preclinical requirements. Reformulation for CNS indication would require bridging PK/PD studies. Estimated $30-80M and 3-4 years to proof-of-concept. |
| Safety Concerns | Modest. Dimethyl fumarate causes gastrointestinal disturbances and flushing. More concerningly, NRF2 activation in peripheral organs (liver, kidney) may cause off-target effects. The theoretical risk of NRF2 promoting tumor cell survival is mitigated by normal neuronal physiology but represents a regulatory concern. |
| Biomarker Readiness | Good. NQO1 and HMOX1 transcript levels in peripheral blood mononuclear cells serve as pharmacodynamic biomarkers. CSF NRF2 target engagement studies are feasible. |
| Therapeutic Window | Narrow but navigable. Excessive NRF2 activation may disrupt essential developmental pruning programs. Target engagement without over-activation is achievable via dose titration. |
| Development Risk | Low-moderate. Mechanism is well-characterized; risk is primarily in demonstrating CNS-specific efficacy rather than target validation. |

Actionable Strategy: Immediate opportunity exists to conduct an adequately powered NRF2 activator trial in early AD. Dimethyl fumarate reformulation with enhanced CNS penetration (targeting fumarate moieties with pro-drug strategies) represents a near-term clinical development pathway.

H1: REST/NRSF

| Dimension | Assessment |
|-----------|------------|
| Druggability | Moderately tractable with indirect approaches. Direct REST agonism faces challenges (transcription factor, nuclear localization). Achievable strategies: (1) CK2 inhibitors to prevent REST degradation, (2) proteasome inhibitors to stabilize residual REST, (3) REST gene therapy via AAV vectors, (4) upstream kinase modulators (calcineurin inhibitors). |
| Existing Compounds | Limited but relevant. CK2 inhibitors are in preclinical/early clinical development (CX-4945 in cancer trials). Calcineurin inhibitors (cyclosporine, tacrolimus) are approved but peripherally restricted due to immunosuppression; blood-brain barrier penetration is poor and risk-benefit does not support AD application. No selective REST activators exist. |
| Clinical Trials in AD | None. REST modulation has not been targeted in any AD trial. |
| Development Cost | High. Requires either novel CK2 inhibitor development ($100-200M, 5-7 years) or AAV-based gene therapy ($200-400M, 6-8 years). Neither represents a near-term opportunity. |
| Safety Concerns | Significant. CK2 is ubiquitously expressed with roles in DNA repair, cell division, and circadian rhythms. Non-selective inhibition could cause chromosomal instability or cancer risk. AAV-mediated REST overexpression carries insertional mutagenesis risk and theoretical oncogenic potential given REST's role in cell cycle regulation. |
| Biomarker Readiness | Emerging. REST protein levels in CSF or neuronal-derived exosomes could serve as pharmacodynamic markers. No validated assay exists for clinical use. |
| Therapeutic Window | Uncertain. Complete REST activation may disrupt essential derepression events during learning and memory consolidation. Partial activation may be insufficient. The "set point" required for therapeutic benefit is unknown. |
| Development Risk | Moderate-high. Target validation in human neurons is incomplete. The mechanistic loop (REST→calcineurin→REST degradation) requires confirmation before therapeutic investment. |

Actionable Strategy: Pursue CK2 inhibitor development as a selective approach, but only following robust target validation in human iPSC-derived neuronal models. The REST hypothesis is more appropriate for mechanistic biomarker development than immediate therapeutic application.

H3: FOXO3-AKT Axis

| Dimension | Assessment |
|-----------|------------|
| Druggability | Moderate. Multiple therapeutic angles exist: (1) AKT inhibitors to permit FOXO3 nuclear translocation, (2) IGF-1R inhibitors to reduce compensatory AKT activation, (3) direct FOXO3 activators (theoretical), (4) upstream insulin sensitizers to modulate the input signal. AKT inhibitors are clinically advanced in oncology. |
| Existing Compounds | Extensive in oncology. AKT inhibitors (ipatasertib, capivasertib) are in phase II/III cancer trials. IGF-1R inhibitors (tes，话axine) were developed for diabetes and cancer but faced efficacy/safety hurdles. No CNS-focused development exists. |
| Clinical Trials in AD | None targeting this axis directly. Insulin intranasal trials (NCT02503501, NCT01767973) suggest insulin signaling manipulation is tolerated in AD. |
| Development Cost | Moderate. AKT inhibitor re-purposing would require dose-finding and safety assessment for chronic CNS indication. Estimated $50-100M and 4-5 years. |
| Safety Concerns | Substantial. AKT inhibitors cause hyperglycemia, GI toxicity, and skin rash in oncology indications—dose-limiting for chronic AD use. The paradox that AD brains exhibit insulin resistance (reducing AKT) suggests systemic AKT inhibition may have unintended consequences. FOXO3 nuclear translocation can activate pro-death programs (FAS) in certain contexts—context-dependent effects are poorly understood. |
| Biomarker Readiness | Good. p-FOXO3(S318) or total FOXO3 nuclear:cytoplasmic ratio in patient-derived neurons could serve as pharmacodynamic marker. |
| Therapeutic Window | Narrow. Systemic AKT inhibition for decades-long AD prevention would be intolerable. Acute intervention during prodromal windows may be more feasible. |
| Development Risk | Moderate-high. The bidirectional nature of AKT-FOXO3 (too much = trapped FOXO3; too little = may impair neuronal function) complicates therapeutic targeting. The hypothesis assumes a therapeutic sweet spot exists. |

Actionable Strategy: Consider insulin sensitizer approach (PPARγ agonists, incretin-based therapies) as an indirect method to modulate the AKT-FOXO3 axis. These agents have established safety profiles and are already in AD clinical trials (pioglitazone, liraglutide). This represents a lower-risk entry point than direct AKT inhibition.

H2: NPAS4-BMAL1 Complex

| Dimension | Assessment |
|-----------|------------|
| Druggability | Challenging. The proposed NPAS4-REV-ERBα dimer switch is mechanistically unproven, limiting rational drug design. Even if validated, the therapeutic goal (restoring BMAL1 partnership over REV-ERBα) has no clear pharmacological solution. REV-ERBα agonists exist (GSK4112) but would drive the "wrong" dimerization. BMAL1 activators do not exist. |
| Existing Compounds | Limited. REV-ERBα agonists and BMAL1 modulators exist in preclinical stage. Sleep interventions (CBT-I, pharmacological) are clinically available but not disease-modifying. |
| Clinical Trials in AD | None. Sleep intervention trials in AD (NCT03811752 - suvorexant) focus on circadian rhythm improvement rather than NPAS4 modulation. |
| Development Cost | High. Requires extensive target validation before therapeutic development. $150-250M and 6-8 years minimum. |
| Safety Concerns | Variable. The circadian manipulation approach (suvorexant trials) appears safe but addresses symptoms rather than pathology. REV-ERBα agonism may have unintended metabolic consequences. |
| Biomarker Readiness | Poor. No validated biomarkers for NPAS4 dimerization status exist. Circadian rhythm markers (cortisol rhythm, actigraphy) are indirect proxies. |
| Therapeutic Window | Theoretical. Unknown. |
| Development Risk | High. Premature for therapeutic investment without fundamental mechanism validation. |

Actionable Strategy: Deprioritize for drug development. Prioritize funding for mechanistic studies in human neuronal models. Circadian/sleep intervention remains a viable lifestyle/behavioral approach independent of NPAS4 biology.

H4: ZNF692-SUZ12/PRC2 Axis

| Dimension | Assessment |
|-----------|------------|
| Druggability | Moderate. EZH2 inhibitors are clinically advanced (tazemetostat approved in epithelioid sarcoma). PRC2 catalytic activity is druggable with small molecules. The challenge is achieving neuron-specific effects without disrupting PRC2 function elsewhere. |
| Existing Compounds | Available. Tazemetostat (EZH2 inhibitor) is FDA-approved. Other EZH2 inhibitors (valemetostat) are in clinical trials for hematologic malignancies. |
| Clinical Trials in AD | None. EZH2 inhibitors are exclusively in oncology development. |
| Development Cost | Moderate-high. Repurposing tazemetostat for AD requires extensive safety characterization (EZH2 inhibitors cause serious adverse events including secondary malignancies). Estimated $80-150M and 4-6 years. |
| Safety Concerns | Significant. Tazemetostat carries FDA black box warning for secondary myeloid malignancies. This risk-benefit calculation is unacceptable for AD unless efficacy is dramatic. Long-term CNS exposure to EZH2 inhibitors may disrupt epigenetic programming essential for cognition. |
| Biomarker Readiness | Good. H3K27me3 levels are quantifiable in CSF exosomes. ChAT activity can be measured as functional endpoint. |
| Therapeutic Window | Narrow. EZH2 inhibition carries genotoxic risk. Neuronal-specific delivery (if achievable) would be essential. |
| Development Risk | Moderate-high. The safety profile of EZH2 inhibitors makes chronic CNS application untenable without substantial reformulation or novel analogs with improved CNS penetration and safety. |

Actionable Strategy: This hypothesis is more valuable for identifying susceptible patient populations (via ChAT+ neuron assessment) than for direct therapeutic targeting. If pursued, would require development of blood-brain barrier-penetrant EZH2 inhibitors with modified safety profiles—essentially a novel drug development program.

H5: LIN28B-let-7 Loop

| Dimension | Assessment |
|-----------|------------|
| Druggability | Challenging. LIN28B is an RNA-binding protein with indirect transcriptional effects. Let-7 mimics exist but face delivery challenges. No selective LIN28B inhibitors exist. |
| Existing Compounds | Emerging. Let-7 mimic oligonucleotides (miRagen, now LUCD Pharma) are in preclinical/early clinical development for oncology. No CNS-targeted development. |
| Clinical Trials in AD | None. |
| Development Cost | Very high. Novel oligonucleotide development with CNS delivery would cost $200-400M and 7-10 years. |
| Safety Concerns | Substantial. Let-7 family targets multiple genes; off-target effects are unpredictable. LIN28B manipulation may disrupt developmental programs. |
| Biomarker Readiness | Emerging. Let-7 levels are measurable via liquid biopsy. |
| Development Risk | High. Confidence score of 0.58 does not justify this investment level. |

Actionable Strategy: Deprioritize. Low confidence score and substantial development barriers make this unsuitable for near-term investment.

H7: TEF-GRX1 Axis

| Dimension | Assessment |
|-----------|------------|
| Druggability | Challenging. TEF is an orphan nuclear receptor with limited characterization. GRX1 is an enzyme; protein replacement is theoretically possible but impractical. |
| Existing Compounds | None specific. Glutaredoxin recombinant proteins are research reagents only. No TEF modulators exist. |
| Clinical Trials in AD | None. |
| Development Cost | Prohibitive. Would require fundamental biology characterization, assay development, lead optimization, and IND-enabling studies de novo. $300-500M and 8-10+ years. |
| Safety Concerns | Unknown. Insufficient biology to assess. |
| Development Risk | Very high. Lowest confidence score combined with highest development cost and lowest mechanistic clarity. |

Actionable Strategy: Do not pursue. Reserve research funding for mechanistic validation only.

Consolidated Practical Feasibility Matrix

| Hypothesis | Target Class | Development Stage | Development Cost | Safety Feasibility | Recommended Action |
|------------|--------------|-------------------|------------------|-------------------|-------------------|
| H6: NRF2-KEAP1 | Well-established | Pre-validated | $30-80M | Acceptable | Priority 1: Advance NRF2 activator trial |
| H1: REST/NRSF | Indirect approach needed | Pre-competitive | $100-200M | Concerning | Priority 2: Validate CK2-REST axis in human neurons |
| H3: FOXO3-AKT | Repurposing possible | Early | $50-100M | Challenging | Priority 3: Explore insulin sensitizer approach |
| H2: NPAS4 | Unproven mechanism | Pre-competitive | $150-250M | Variable | Defer; mechanistic validation required |
| H4: PRC2/EZH2 | Repurposing possible | Available | $80-150M | Significant risk | Low priority; biomarker utility |
| H5: LIN28B | Novel modality | Early | $200-400M | Uncertain | Defer; low confidence |
| H7: TEF-GRX1 | Novel target | Pre-competitive | $300-500M | Unknown | Do not pursue |

Strategic Recommendations

Immediate Clinical Entry (0-3 years)

• Approved drugs with relevant mechanism of action
• Established safety databases
• Clear biomarker readouts
• Measurable pharmacodynamic endpoints